Ductal adenocarcimoma of the prostate is “rare” but aggressive

Pure ductal adenocarcinoma of the prostate (dPC) is thought to be found in just 0.4 to 0.8 percent of men who get diagnosed with prostate cancer each year. … READ MORE …

Medicare to cover genetic/genomic testing in advanced cancers

In an important decision announced late on Friday last week, the Centers for Medicare & Medicaid Services (CMS) announced that it had agreed to cover costs associated with genetic/genomic testing for Medicare patients with many advanced forms of cancer. … READ MORE …

Some “Best of ASCO” reports from UroToday

The UroToday web site has now posted a number of “Best of ASCO” reports that might be of interest to some of our readers. … READ MORE …

Just how helpful is personalized genomic analysis anyway?

Regular readers of the medical science literature will be very conscious of the emphasis on genomic analysis of tumor specimens as a way to try to “personalize” treatment of cancers of many types — prostate cancer very specifically included. … READ MORE …

Factors in the sequencing of late-stage prostate cancer treatments

A paper in the International Journal of Cancer offers information on the sequencing of cabazitaxel (CAB) and abiraterone acetate (ABI) in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already progressed after treatment with docetaxel. … READ MORE …

Sipuleucel-T before or after ADT in men with biochemically recurrent disease?

A paper to be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago is entitled, “A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): immune results.” … READ MORE …

Responses to abiraterone + prednisone after docetaxel and enzalutamide in men with mCRPC

Two new papers offer us some preliminary information about the activity of abiraterone acetate in men with metastatic, castration-resistant prostate cancer (mCRPC) after prior treatment with docetaxel-based chemotherapy and with enzalutamide. … READ MORE …